Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Revvity Inc (RVTY) Price & Performance

Blackrock IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Revvity Inc — how do they compare? Blackrock Inc trades at $1,157.88 (market cap $177.92B), while Revvity Inc trades at $116.33 (market cap $12.91B). The key difference: Blackrock Inc is far larger — about 13.8× Revvity Inc's market cap, and Blackrock Inc pays the higher dividend (2%). Which is the better fit depends on your goals.

BLKRVTY
Market Cap
$177.92B$12.91B
Volume
641,547
Sector
FinancialsTechnology
52-Week High
$1.20K$117.75
52-Week Low
$922.90$82.26
Enterprise Value
$179.02B$15.23B
Dividend Yield
2%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BlackRock (BLK) trades at $1,153.57, up 1.96% today, reflecting strong momentum. The stock shows bullish technical signals with consistent earnings beats in recent quarters, including Q2 2026 EPS of $13.91 versus $12.69 expected. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with partners like Apollo and Nvidia, signaling strategic growth avenues.

The outlook remains positive with a consensus price target of $1,350, implying 17% upside. Key opportunities include robust analyst support (79% buy ratings) and dividend stability, while risks involve legal investigations into mutual fund practices and volatile cash flows, with net cash flow negative $1.29 billion in 2025. Investors should weigh solid fundamentals against regulatory and execution risks.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY